The Science and Hope of Brain Cancer with Dr. Robert Thorne, Denali Therapeutics

In this powerful episode (#35) of BioTalk Unzipped, recorded live at the AAPS NBC conference in Boston, Gregory Austin engages in a deep conversation with a leading Neuroscientist, Dr. Robert Thorne, Denali Fellow at Denali Therapeutics, for an intimate and scientific deep dive into the evolving world of brain cancer treatment and CNS drug delivery. Both Gregory and Dr. Thorne share personal stories of losing family members to brain metastases, weaving in the emotional 'why' behind their professional paths.

Dr. Thorne highlights the complexities of the blood-brain barrier, the heterogeneity of brain metastases, and cutting-edge delivery technologies—including focused ultrasound and molecular engineering approaches. The conversation also touches on pediatric brain tumors like diffuse midline glioma (DIPG), emerging research in lysosomal storage diseases, and the collaborative spirit driving innovation in neuroscience today.

This is more than a technical discussion—it’s a human story about grief, hope, and the relentless pursuit of better outcomes for patients with brain diseases.

00:00 Preview & Intro

01:10 Robert Thorne’s Reflections on the AAPS NBC conference

03:14 The Professional Biotech and Pharma League

05:09 A Personal Story Shared: Family Loss to Brain Cancer

07:57 My Reason for Optimism Treating Brain Cancer

08:50 Why Brain Metastases Remain Hard to Treat

11:10 Scientific Advances in Drug Delivery for Brain Cancer

12:30 Seed and Soil Concept in Oncology

15:18 Pediatric Brain Tumors: DNET, DIPG, and Beyond

16:49 Looking Ahead: Hope for Future Therapies

21:32 Closing Gratitude

Dr. Robert Thorne

https://www.linkedin.com/in/robert-g-thorne/

Denali Therapeutics - https://www.denalitherapeutics.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Celerion - https://www.celerion.com/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

Celerion - https://www.celerion.com/

Key Takeaways:

• Personal Connection Fuels Professional Passion: Both Gregory and Dr. Thorne were driven into the life sciences field by family experiences with brain tumors.

• The Blood-Brain Barrier (BBB) Remains a Major Challenge: Brain metastases from cancers like melanoma, lung, and breast cancer still present difficult delivery barriers for therapies.

• Heterogeneity in Brain Mets: Different metastases within the same patient can have vastly different BBB permeability, requiring multifaceted delivery strategies.

• Emerging Drug Delivery Innovations: Focused ultrasound, engineered biologics, and Denali’s own delivery platforms are all promising ways to improve CNS drug penetration.

• Pediatric Brain Cancers Present a Unique Set of Challenges: Diseases like diffuse midline glioma (DIPG) remain largely untreatable, but learnings from lysosomal storage disorders may translate in the future.

• The Power of Community in Science: The conference setting highlights how collaboration and diverse perspectives drive breakthroughs in bioanalysis and drug development.